Açaí (Euterpe olecareae Martius) intake and its protective effect against 1,2-DMH-induced rat colon carcinogenesis
© Fragoso and Barbisan; licensee BioMed Central Ltd. 2013
Published: 4 April 2013
Açaí (Euterpe olecareae Martius) is an important crop consumed in Brazil that gained attention due to its potential antioxidant and anti-inflammatory properties. Various studies have shown that this exotic fruit may reduce the risk of many diseases, including cancer. The present study investigated the beneficial potential of açaí extract intake on the 1,2-dimethylhydrazine (DMH)-induced rat colon carcinogenesis.
Materials and methods
Five groups were studied: G1 to G4 groups received four s.c. injections of DMH (40 mg/kg) twice a week during two weeks and G5 group received similar injections of EDTA (DMH vehicle). After two weeks of colon initiation, groups were fed basal diet (G1), basal diet containing 2.5% açaí extract (G2), basal diet containing 5.0% açaí extract (G3 and G5) or basal diet containing 0.2% of N-acetylcysteine (G4, positive control). Ten weeks after the beginning of the treatment, G1 to G4 groups were sacrificed for aberrant crypt foci (ACF) assay. Also, G1 and G3 groups were maintained on basal diet or basal diet containing 5.0% açaí extract, respectively, until week 20. Colons were analyzed for ACF development (week 10) or tumor incidence, multiplicity and histological analyses (week 20).
The number of total aberrant crypts (AC) was significantly reduced in G3 and G4 groups when compared to G1 group (p=0.036). Data from ACF (1-3 AC) was significantly lower in G3 and G4 groups (p=0.011 and p=0.037, respectively). In the colon tumor assay, G1 group developed invasive (75%) and noninvasive (25%) tumors whereas G3 group developed only noninvasive tumors (100%).
These results suggest that açaí extract intake is potentially beneficial for early reduction of the number of AC and may affect tumor development and late malignancy in male Wistar rats initiated for colon carcinogenesis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.